Cargando…
The influence of dapagliflozin on cardiac remodeling, myocardial function and metabolomics in type 1 diabetes mellitus rats
BACKGROUND: Sodium-glucose cotransporter (SGLT)2 inhibitors have displayed beneficial effects on the cardiovascular system in diabetes mellitus (DM) patients. As most clinical trials were performed in Type 2 DM, their effects in Type 1 DM have not been established. OBJECTIVE: To evaluate the influen...
Autores principales: | , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10617150/ https://www.ncbi.nlm.nih.gov/pubmed/37908006 http://dx.doi.org/10.1186/s13098-023-01196-6 |
_version_ | 1785129544072560640 |
---|---|
author | Rodrigues, Eder Anderson Rosa, Camila Moreno Campos, Dijon Henrique Salome Damatto, Felipe Cesar Murata, Gilson Masahiro Souza, Lidiane Moreira Pagan, Luana Urbano Gatto, Mariana Brosler, Jessica Yumi Souza, Hebreia Oliveira Almeida Martins, Mario Machado Bastos, Luciana Machado Tanni, Suzana Erico Okoshi, Katashi Okoshi, Marina Politi |
author_facet | Rodrigues, Eder Anderson Rosa, Camila Moreno Campos, Dijon Henrique Salome Damatto, Felipe Cesar Murata, Gilson Masahiro Souza, Lidiane Moreira Pagan, Luana Urbano Gatto, Mariana Brosler, Jessica Yumi Souza, Hebreia Oliveira Almeida Martins, Mario Machado Bastos, Luciana Machado Tanni, Suzana Erico Okoshi, Katashi Okoshi, Marina Politi |
author_sort | Rodrigues, Eder Anderson |
collection | PubMed |
description | BACKGROUND: Sodium-glucose cotransporter (SGLT)2 inhibitors have displayed beneficial effects on the cardiovascular system in diabetes mellitus (DM) patients. As most clinical trials were performed in Type 2 DM, their effects in Type 1 DM have not been established. OBJECTIVE: To evaluate the influence of long-term treatment with SGLT2 inhibitor dapagliflozin on cardiac remodeling, myocardial function, energy metabolism, and metabolomics in rats with Type 1 DM. METHODS: Male Wistar rats were divided into groups: Control (C, n = 15); DM (n = 15); and DM treated with dapagliflozin (DM + DAPA, n = 15) for 30 weeks. DM was induced by streptozotocin. Dapagliflozin 5 mg/kg/day was added to chow. Statistical analysis: ANOVA and Tukey or Kruskal-Wallis and Dunn. RESULTS: DM + DAPA presented lower glycemia and higher body weight than DM. Echocardiogram showed DM with left atrium dilation and left ventricular (LV) hypertrophy, dilation, and systolic and diastolic dysfunction. In LV isolated papillary muscles, DM had reduced developed tension, +dT/dt and -dT/dt in basal condition and after inotropic stimulation. All functional changes were attenuated by dapagliflozin. Hexokinase (HK), phosphofructokinase (PFK) and pyruvate kinase (PK) activity was lower in DM than C, and PFK and PK activity higher in DM + DAPA than DM. Metabolomics revealed 21 and 5 metabolites positively regulated in DM vs. C and DM + DAPA vs. DM, respectively; 6 and 3 metabolites were negatively regulated in DM vs. C and DM + DAPA vs. DM, respectively. Five metabolites that participate in cell membrane ultrastructure were higher in DM than C. Metabolites levels of N-oleoyl glutamic acid, chlorocresol and N-oleoyl-L-serine were lower and phosphatidylethanolamine and ceramide higher in DM + DAPA than DM. CONCLUSION: Long-term treatment with dapagliflozin attenuates cardiac remodeling, myocardial dysfunction, and contractile reserve impairment in Type 1 diabetic rats. The functional improvement is combined with restored pyruvate kinase and phosphofructokinase activity and attenuated metabolomics changes. |
format | Online Article Text |
id | pubmed-10617150 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-106171502023-11-01 The influence of dapagliflozin on cardiac remodeling, myocardial function and metabolomics in type 1 diabetes mellitus rats Rodrigues, Eder Anderson Rosa, Camila Moreno Campos, Dijon Henrique Salome Damatto, Felipe Cesar Murata, Gilson Masahiro Souza, Lidiane Moreira Pagan, Luana Urbano Gatto, Mariana Brosler, Jessica Yumi Souza, Hebreia Oliveira Almeida Martins, Mario Machado Bastos, Luciana Machado Tanni, Suzana Erico Okoshi, Katashi Okoshi, Marina Politi Diabetol Metab Syndr Research BACKGROUND: Sodium-glucose cotransporter (SGLT)2 inhibitors have displayed beneficial effects on the cardiovascular system in diabetes mellitus (DM) patients. As most clinical trials were performed in Type 2 DM, their effects in Type 1 DM have not been established. OBJECTIVE: To evaluate the influence of long-term treatment with SGLT2 inhibitor dapagliflozin on cardiac remodeling, myocardial function, energy metabolism, and metabolomics in rats with Type 1 DM. METHODS: Male Wistar rats were divided into groups: Control (C, n = 15); DM (n = 15); and DM treated with dapagliflozin (DM + DAPA, n = 15) for 30 weeks. DM was induced by streptozotocin. Dapagliflozin 5 mg/kg/day was added to chow. Statistical analysis: ANOVA and Tukey or Kruskal-Wallis and Dunn. RESULTS: DM + DAPA presented lower glycemia and higher body weight than DM. Echocardiogram showed DM with left atrium dilation and left ventricular (LV) hypertrophy, dilation, and systolic and diastolic dysfunction. In LV isolated papillary muscles, DM had reduced developed tension, +dT/dt and -dT/dt in basal condition and after inotropic stimulation. All functional changes were attenuated by dapagliflozin. Hexokinase (HK), phosphofructokinase (PFK) and pyruvate kinase (PK) activity was lower in DM than C, and PFK and PK activity higher in DM + DAPA than DM. Metabolomics revealed 21 and 5 metabolites positively regulated in DM vs. C and DM + DAPA vs. DM, respectively; 6 and 3 metabolites were negatively regulated in DM vs. C and DM + DAPA vs. DM, respectively. Five metabolites that participate in cell membrane ultrastructure were higher in DM than C. Metabolites levels of N-oleoyl glutamic acid, chlorocresol and N-oleoyl-L-serine were lower and phosphatidylethanolamine and ceramide higher in DM + DAPA than DM. CONCLUSION: Long-term treatment with dapagliflozin attenuates cardiac remodeling, myocardial dysfunction, and contractile reserve impairment in Type 1 diabetic rats. The functional improvement is combined with restored pyruvate kinase and phosphofructokinase activity and attenuated metabolomics changes. BioMed Central 2023-10-31 /pmc/articles/PMC10617150/ /pubmed/37908006 http://dx.doi.org/10.1186/s13098-023-01196-6 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Rodrigues, Eder Anderson Rosa, Camila Moreno Campos, Dijon Henrique Salome Damatto, Felipe Cesar Murata, Gilson Masahiro Souza, Lidiane Moreira Pagan, Luana Urbano Gatto, Mariana Brosler, Jessica Yumi Souza, Hebreia Oliveira Almeida Martins, Mario Machado Bastos, Luciana Machado Tanni, Suzana Erico Okoshi, Katashi Okoshi, Marina Politi The influence of dapagliflozin on cardiac remodeling, myocardial function and metabolomics in type 1 diabetes mellitus rats |
title | The influence of dapagliflozin on cardiac remodeling, myocardial function and metabolomics in type 1 diabetes mellitus rats |
title_full | The influence of dapagliflozin on cardiac remodeling, myocardial function and metabolomics in type 1 diabetes mellitus rats |
title_fullStr | The influence of dapagliflozin on cardiac remodeling, myocardial function and metabolomics in type 1 diabetes mellitus rats |
title_full_unstemmed | The influence of dapagliflozin on cardiac remodeling, myocardial function and metabolomics in type 1 diabetes mellitus rats |
title_short | The influence of dapagliflozin on cardiac remodeling, myocardial function and metabolomics in type 1 diabetes mellitus rats |
title_sort | influence of dapagliflozin on cardiac remodeling, myocardial function and metabolomics in type 1 diabetes mellitus rats |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10617150/ https://www.ncbi.nlm.nih.gov/pubmed/37908006 http://dx.doi.org/10.1186/s13098-023-01196-6 |
work_keys_str_mv | AT rodriguesederanderson theinfluenceofdapagliflozinoncardiacremodelingmyocardialfunctionandmetabolomicsintype1diabetesmellitusrats AT rosacamilamoreno theinfluenceofdapagliflozinoncardiacremodelingmyocardialfunctionandmetabolomicsintype1diabetesmellitusrats AT camposdijonhenriquesalome theinfluenceofdapagliflozinoncardiacremodelingmyocardialfunctionandmetabolomicsintype1diabetesmellitusrats AT damattofelipecesar theinfluenceofdapagliflozinoncardiacremodelingmyocardialfunctionandmetabolomicsintype1diabetesmellitusrats AT muratagilsonmasahiro theinfluenceofdapagliflozinoncardiacremodelingmyocardialfunctionandmetabolomicsintype1diabetesmellitusrats AT souzalidianemoreira theinfluenceofdapagliflozinoncardiacremodelingmyocardialfunctionandmetabolomicsintype1diabetesmellitusrats AT paganluanaurbano theinfluenceofdapagliflozinoncardiacremodelingmyocardialfunctionandmetabolomicsintype1diabetesmellitusrats AT gattomariana theinfluenceofdapagliflozinoncardiacremodelingmyocardialfunctionandmetabolomicsintype1diabetesmellitusrats AT broslerjessicayumi theinfluenceofdapagliflozinoncardiacremodelingmyocardialfunctionandmetabolomicsintype1diabetesmellitusrats AT souzahebreiaoliveiraalmeida theinfluenceofdapagliflozinoncardiacremodelingmyocardialfunctionandmetabolomicsintype1diabetesmellitusrats AT martinsmariomachado theinfluenceofdapagliflozinoncardiacremodelingmyocardialfunctionandmetabolomicsintype1diabetesmellitusrats AT bastoslucianamachado theinfluenceofdapagliflozinoncardiacremodelingmyocardialfunctionandmetabolomicsintype1diabetesmellitusrats AT tannisuzanaerico theinfluenceofdapagliflozinoncardiacremodelingmyocardialfunctionandmetabolomicsintype1diabetesmellitusrats AT okoshikatashi theinfluenceofdapagliflozinoncardiacremodelingmyocardialfunctionandmetabolomicsintype1diabetesmellitusrats AT okoshimarinapoliti theinfluenceofdapagliflozinoncardiacremodelingmyocardialfunctionandmetabolomicsintype1diabetesmellitusrats AT rodriguesederanderson influenceofdapagliflozinoncardiacremodelingmyocardialfunctionandmetabolomicsintype1diabetesmellitusrats AT rosacamilamoreno influenceofdapagliflozinoncardiacremodelingmyocardialfunctionandmetabolomicsintype1diabetesmellitusrats AT camposdijonhenriquesalome influenceofdapagliflozinoncardiacremodelingmyocardialfunctionandmetabolomicsintype1diabetesmellitusrats AT damattofelipecesar influenceofdapagliflozinoncardiacremodelingmyocardialfunctionandmetabolomicsintype1diabetesmellitusrats AT muratagilsonmasahiro influenceofdapagliflozinoncardiacremodelingmyocardialfunctionandmetabolomicsintype1diabetesmellitusrats AT souzalidianemoreira influenceofdapagliflozinoncardiacremodelingmyocardialfunctionandmetabolomicsintype1diabetesmellitusrats AT paganluanaurbano influenceofdapagliflozinoncardiacremodelingmyocardialfunctionandmetabolomicsintype1diabetesmellitusrats AT gattomariana influenceofdapagliflozinoncardiacremodelingmyocardialfunctionandmetabolomicsintype1diabetesmellitusrats AT broslerjessicayumi influenceofdapagliflozinoncardiacremodelingmyocardialfunctionandmetabolomicsintype1diabetesmellitusrats AT souzahebreiaoliveiraalmeida influenceofdapagliflozinoncardiacremodelingmyocardialfunctionandmetabolomicsintype1diabetesmellitusrats AT martinsmariomachado influenceofdapagliflozinoncardiacremodelingmyocardialfunctionandmetabolomicsintype1diabetesmellitusrats AT bastoslucianamachado influenceofdapagliflozinoncardiacremodelingmyocardialfunctionandmetabolomicsintype1diabetesmellitusrats AT tannisuzanaerico influenceofdapagliflozinoncardiacremodelingmyocardialfunctionandmetabolomicsintype1diabetesmellitusrats AT okoshikatashi influenceofdapagliflozinoncardiacremodelingmyocardialfunctionandmetabolomicsintype1diabetesmellitusrats AT okoshimarinapoliti influenceofdapagliflozinoncardiacremodelingmyocardialfunctionandmetabolomicsintype1diabetesmellitusrats |